Acquisition of an Illumina Genome Analyzer for The Research Institute

描述（由申请人提供）： 下一代测序技术彻底改变了基因组学研究。 它在了解人类健康和疾病方面具有巨大的潜力。在全国儿童医院研究所购买下一代测序仪对于履行我们的承诺至关重要，即根据最高的科学和道德标准进行高质量的尖端研究，以增强儿童的健康。在本提案中，我们申请资金以收购Illumina基因组分析仪IIx。 我们有效地展示了来自我们六个重点研究中心的十二名NIH资助的生物医学研究调查人员如何在他们的高影响力研究中利用现场下一代测序仪。随着我们的研究项目不断扩大，我们预计对这项技术的需求将不断增长。获得这一工具和生物医学基因组学核心的拟议支持将特别有助于年轻的研究人员，博士后研究科学家，医生科学家和临床研究员。鉴于这项技术将对我们的研究产生的影响，研究所承诺提供超过25万美元的资金，以确保这项技术得到迅速部署和充分支持。此外，该研究所致力于为这项技术提供长期的财政支持，并提供运行该技术所需的人员。收购该仪器将使我们能够继续扩大我们在战略重点领域的计划，即围产期研究，传染病研究，儿童先天性和后天性心脏病，消化系统疾病和儿童癌症。作为全国十大独立儿童医院研究机构之一，我们的研究已经证明它对健康有很大的影响。Illumina基因组分析仪IIx系统将为我们的研究机构带来技术上最先进的基因组学功能，并将极大地提高我们进行与儿科健康和疾病相关的基因组学研究的能力。

DESCRIPTION (provided by applicant): Next-generation sequencing technology has revolutionized genomics research. It has tremendous potential for understanding human health and disease. The acquisition of a next-generation sequencer at The Research Institute at Nationwide Children's Hospital is essential to meet our commitment to enhance the health of children by engaging in high quality, cutting-edge research according to the highest scientific and ethical standards. In this proposal, we apply for funding to acquire an Illumina Genome Analyzer IIx. We effectively demonstrate how twelve NIH-funded biomedical research investigators from six of our Research Centers of Emphasis can utilize an on-site next-generation sequencer in their high-impact research. As our research program continues to expand, we anticipate that the demand for this technology will grow. Access to this instrument and the proposed support from the Biomedical Genomics Core will be particularly helpful for young investigators, postdoctoral research scientists, physician scientists and clinical fellows. In light of the impact that this technology will have on our research, The Research Institute is committing over $250,000 to ensure that the technology is rapidly deployed and fully supported. Furthermore, The Research Institute is committed to providing the long-term financial support for this technology and the staff required run it. Acquisition of this instrument will allow us to continue expanding our programs in areas of strategic emphasis, namely perinatal research, infectious diseases research, congenital and acquired disorders of the heart in children, digestive diseases and childhood cancer. Being one of the top 10 independent Children's Hospital Research Institutes in the country, our research has already demonstrated that it has a strong impact with relevance to health. The Illumina Genome Analyzer IIx System will bring the most technologically advanced genomics capabilities to our research institute and will immeasurably improve our ability to conduct genomics research relevant to pediatric health and disease.